San Antonio Breast Cancer Symposium
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
SABCS Studies Show Promise of ctDNA Analysis in Individualizing CDK4/6 Inhibitor, Endocrine Therapy
Premium
Researchers investigated the potential of liquid biopsy testing to help patients avoid endocrine resistance in the PADA-1 trial and identify best responders in the BioltaLEE trial.
Researchers ID Genomic Signature to Risk Stratify Patients With Precancerous Breast Lesions
In the study, presented at SABCS, researchers developed an 812-gene signature that could identify which patients with ductal carcinoma in situ need aggressive treatment.
Real-World Data Points to Racial Disparity in BRCA1/2 Testing Among TNBC Patients
Researchers analyzed data from Syapse's Learning Health Network and found that more Black patients were unable to be tested or declined it compared to white patients.
SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance
Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.